$ABUS
Arbutus Biopharma Corp Stock $abus

$abus Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000144702822000055 Filed on November 09, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$6.245M	$5.952M	$3.340M
YoY Change	94.79%	78.2%	119.3%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.249M	$3.493M	$4.146M
YoY Change	-9.56%	-15.75%	1.87%
% of Gross Profit
Research & Development	$22.95M	$20.06M	$16.30M
YoY Change	12.29%	23.04%	35.09%
% of Gross Profit
Depreciation & Amortization	$307.0K	$343.0K	$447.0K
YoY Change	-28.1%	-23.27%	-8.78%
% of Gross Profit
Operating Expenses	$28.81M	$23.76M	$21.75M
YoY Change	20.02%	9.27%	29.92%
Operating Profit		-$17.81M	-$18.41M
YoY Change		-3.24%	20.97%
Interest Expense	$630.0K	$429.0K	$762.0K
YoY Change	-220.0%	-43.7%	-29.05%
% of Operating Profit
Other Income/Expense, Net		$244.0K	-$750.0K
YoY Change		-132.53%	-78.8%
Pretax Income	-$21.93M	-$17.57M	-$19.16M
YoY Change	2.87%	-8.3%	2.15%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$21.93M	-$17.57M	-$19.16M
YoY Change	2.87%	-8.3%	2.15%
Net Earnings / Revenue	-351.19%	-295.14%	-573.59%
Basic Earnings Per Share		-$0.12	-$0.24
Diluted Earnings Per Share	-$0.14	-$0.12	-$0.24
COMMON SHARES
Basic Shares Outstanding	156.5M shares	150.0M shares	101.3M shares
Diluted Shares Outstanding		151.0M shares	101.3M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$146.9M	$134.7M	$121.4M
YoY Change	-5.41%	10.97%	2.63%
Cash & Equivalents	$30.78M	$24.00M	$77.88M
Short-Term Investments	$116.1M	$110.7M	$43.52M
Other Short-Term Assets	$2.874M	$4.583M	$3.466M
YoY Change	-35.34%	32.23%	82.42%
Inventory
Prepaid Expenses
Receivables	$1.352M	$1.835M	$1.667M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$151.1M	$141.1M	$126.5M
YoY Change	-5.93%	11.54%	4.37%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.070M	$5.241M	$6.352M
YoY Change	-15.26%	-17.49%	-12.53%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$0.00	$0.00
YoY Change
Other Assets	$103.0K	$167.0K	$0.00
YoY Change	68.85%		-100.0%
Total Long-Term Assets	$44.28M	$62.67M	$39.06M
YoY Change	1.04%	60.43%	296.07%
TOTAL ASSETS
Total Short-Term Assets	$151.1M	$141.1M	$126.5M
Total Long-Term Assets	$44.28M	$62.67M	$39.06M
Total Assets	$195.4M	$203.8M	$165.6M
YoY Change	-4.43%	23.07%	26.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.520M	$872.0K	$1.042M
YoY Change	10.9%	-16.31%	15.78%
Accrued Expenses	$12.88M	$11.76M	$9.034M
YoY Change	60.59%	30.13%	41.16%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$32.86M	$27.51M	$10.11M
YoY Change	192.82%	171.99%	32.93%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$25.71M	$30.78M	$25.34M
YoY Change	7.91%	21.45%	-3.27%
Total Long-Term Liabilities	$25.71M	$30.78M	$25.34M
YoY Change	7.91%	21.45%	-3.27%
TOTAL LIABILITIES
Total Short-Term Liabilities	$32.86M	$27.51M	$10.11M
Total Long-Term Liabilities	$25.71M	$30.78M	$25.34M
Total Liabilities	$58.57M	$58.28M	$35.46M
YoY Change	67.11%	64.38%	5.03%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.204B	-$1.182B	-$1.112B
YoY Change	6.12%	6.24%	8.45%
Common Stock	$1.319B	$1.308B	$1.066B
YoY Change	2.49%	22.7%	10.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$136.9M	$145.5M	$130.1M
YoY Change
Total Liabilities & Shareholders Equity	$195.4M	$203.8M	$165.6M
YoY Change	-4.43%	23.07%	26.31%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$21.93M	-$17.57M	-$19.16M
YoY Change	2.87%	-8.3%	2.15%
Depreciation, Depletion And Amortization	$307.0K	$343.0K	$447.0K
YoY Change	-28.1%	-23.27%	-8.78%
Cash From Operating Activities	-$16.99M	-$18.69M	-$16.04M
YoY Change	-13.34%	16.56%	31.66%
INVESTING ACTIVITIES
Capital Expenditures	$134.0K	-$91.00K	-$20.00K
YoY Change	-331.03%	355.0%	100.0%
Acquisitions
YoY Change
Other Investing Activities	$12.82M	-$13.65M	$15.99M
YoY Change	-258.95%	-185.35%	13.4%
Cash From Investing Activities	$12.68M	-$13.74M	$15.97M
YoY Change	-256.16%	-186.03%	13.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	11.08M	9.132M	46.95M
YoY Change	-81.25%	-80.55%	-4.37%
NET CHANGE
Cash From Operating Activities	-16.99M	-18.69M	-16.04M
Cash From Investing Activities	12.68M	-13.74M	15.97M
Cash From Financing Activities	11.08M	9.132M	46.95M
Net Change In Cash	6.776M	-23.30M	46.89M
YoY Change	-78.42%	-149.69%	-8.1%
FREE CASH FLOW
Cash From Operating Activities	-$16.99M	-$18.69M	-$16.04M
Capital Expenditures	$134.0K	-$91.00K	-$20.00K
Free Cash Flow	-$17.12M	-$18.60M	-$16.02M
YoY Change	-12.4%	16.14%	31.6%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001447028
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-34949
	dei	Entity Registrant Name EntityRegistrantName	ARBUTUS BIOPHARMA CORP
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	A1
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-0597776
	dei	Entity Address Address Line1 EntityAddressAddressLine1	701 Veterans Circle
	dei	Entity Address City Or Town EntityAddressCityOrTown	Warminster
	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	18974
	dei	City Area Code CityAreaCode	267
	dei	Local Phone Number LocalPhoneNumber	469-0914
	dei	Security12b Title Security12bTitle	Common Shares, without par value
	dei	Trading Symbol TradingSymbol	ABUS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	156467085	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24004000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	109282000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	110714000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	46035000	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1835000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	899000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4583000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4445000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	141136000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	160661000	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10475000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9374000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5241000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5983000	usd
CY2022Q3	us-gaap	Long Term Investments LongTermInvestments	55436000	usd
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	35688000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1821000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2092000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	167000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	61000	usd
CY2022Q3	us-gaap	Assets Assets	203801000	usd
CY2021Q4	us-gaap	Assets Assets	204485000	usd
CY2022Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	12268000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	10838000	usd
CY2022Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	14878000	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	360000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	383000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	27506000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11221000	usd
CY2022Q3	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	12316000	usd
CY2021Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	16296000	usd
CY2022Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	10585000	usd
CY2021Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	usd
CY2022Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	5922000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	5298000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1955000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2231000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	58284000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	35046000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	35046000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	35046000	usd
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	152711702	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	152711702	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	144987736	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	144987736	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	1307654000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1286636000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	70738000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	65485000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1181871000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1134347000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-51004000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-48335000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	145517000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	169439000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	203801000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	204485000	usd
CY2022Q3	us-gaap	Revenues Revenues	5952000	usd
CY2021Q3	us-gaap	Revenues Revenues	3340000	usd
	us-gaap	Revenues Revenues	32774000	usd
	us-gaap	Revenues Revenues	7782000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20055000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16709000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	61459000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	46290000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3493000	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4183000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13585000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12539000	usd
CY2022Q3	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	215000	usd
CY2021Q3	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	856000	usd
	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	624000	usd
	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	1679000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	23763000	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	21748000	usd
	us-gaap	Operating Expenses OperatingExpenses	75668000	usd
	us-gaap	Operating Expenses OperatingExpenses	60508000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-17811000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-18408000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-42894000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-52726000	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	694000	usd
CY2021Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	27000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1249000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	97000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	429000	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	762000	usd
	us-gaap	Interest Expense InterestExpense	1417000	usd
	us-gaap	Interest Expense InterestExpense	2297000	usd
CY2022Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-21000	usd
CY2021Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-15000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-18000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	244000	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-750000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-186000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2200000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17567000	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19158000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-43080000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-54926000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4444000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-17567000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-19158000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-47524000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-54926000	usd
CY2022Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0	usd
CY2021Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	5087000	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	11565000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17567000	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24245000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-47524000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-66491000	usd
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.68
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.68
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	150995191	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	150995191	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101286351	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	101286351	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	149385999	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	149385999	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97174253	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97174253	shares
CY2022Q3	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-907000	usd
CY2021Q3	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-31000	usd
	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-2669000	usd
	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-16000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18474000	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19189000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-50193000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-54942000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	169439000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1736000	usd
CY2022Q1	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	21000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	236000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1071000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-15765000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	165845000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2064000	usd
CY2022Q2	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	3000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	113000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-691000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-14192000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	153142000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1715000	usd
CY2022Q3	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	2000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8973000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	159000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-907000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-17567000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	145517000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	101966000	usd
CY2021Q1	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	0	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1647000	usd
CY2021Q1	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	40000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	26419000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	208000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	247000	usd
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	3000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-16381000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	114149000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1758000	usd
CY2021Q2	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	51000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4274000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	15000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-31000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-19387000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	100829000	usd
CY2021Q3	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	0	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1549000	usd
CY2021Q3	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	-44000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	44736000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2002000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	214000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	12000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-19158000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	130140000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-47524000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-54926000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1120000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1326000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	20000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5515000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4993000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	624000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1679000	usd
	abus	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	5393000	usd
	abus	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	3963000	usd
	abus	Non Cash Interest Expense Related To Sale Of Future Royalties NonCashInterestExpenseRelatedToSaleOfFutureRoyalties	1413000	usd
	abus	Non Cash Interest Expense Related To Sale Of Future Royalties NonCashInterestExpenseRelatedToSaleOfFutureRoyalties	2292000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-170000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-753000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	936000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	355000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-27000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	67000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1456000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	585000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	25463000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-281000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-243000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18366000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-47926000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	117266000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	54156000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	30000000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	50350000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	20000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	378000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	751000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-87624000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4557000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	121000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2225000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	395000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	461000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20730000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	78115000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-18000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-85278000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	25632000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	109282000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52251000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24004000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	77883000	usd
	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	0	usd
	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	11565000	usd
	us-gaap	Nature Of Operations NatureOfOperations	Nature of business and future operations<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Description of the Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Arbutus Biopharma Corporation (“Arbutus” or the “Company”) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. The Company’s current focus areas include Hepatitis B virus (“HBV”), SARS-CoV-2, and coronaviruses. In HBV, the Company is developing an RNA interference (“RNAi”) therapeutic, an oral PD-L1 inhibitor, and an oral RNA destabilizer to potentially identify a combination regimen with the aim of providing a functional cure for patients with chronic HBV infection (“cHBV”) by suppressing viral replication, reducing surface antigen and reawakening the immune system. The Company believes its lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening, and is currently being evaluated in multiple phase 2 clinical trials. The Company has an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronaviruses, including SARS-CoV-2. The Company is also exploring oncology applications for its internal PD-L1 portfolio.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidity</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022, the Company had an aggregate of $190.2 million in cash, cash equivalents and investments in marketable securities. The Company had no outstanding debt as of September 30, 2022. The Company believes it has sufficient cash resources to fund its operations for at least the next 12 months. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieve profitable operations. The Company’s research and development activities and the commercialization of its products are dependent on its ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of the Company’s existing or future research and development programs or the Company’s ability to continue to fund these programs in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">COVID-19 Impact</span></div>The COVID-19 pandemic has resulted in and will likely continue to result in significant disruptions to businesses. Measures implemented around the world in attempts to slow the spread of COVID-19 have had, and will likely continue to have, a major impact on clinical development, at least in the near-term, including shortages and delays in the supply chain and prohibitions in certain countries on enrolling patients in new clinical trials. While the Company has been able to progress with its clinical and pre-clinical activities to date, it is not possible to predict if the COVID-19 pandemic will materially impact the Company’s plans and timelines in the future.
CY2022Q3	us-gaap	Investments And Cash InvestmentsAndCash	190200000	usd
CY2022Q3	us-gaap	Long Term Debt LongTermDebt	0	usd
CY2022Q3	abus	Wholly Owned Subsidiaries Includedin Financial Statements WhollyOwnedSubsidiariesIncludedinFinancialStatements	1	subsidiary
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	34300000	shares
CY2021Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	22833922	shares
CY2022Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	5900000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	600000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	5298000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	624000	usd
CY2022Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	5922000	usd
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3426000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1679000	usd
CY2021Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	5105000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	56773000	usd
CY2022Q3	us-gaap	Debt Securities Noncurrent DebtSecuritiesNoncurrent	55436000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	35775000	usd
CY2021Q4	us-gaap	Debt Securities Noncurrent DebtSecuritiesNoncurrent	35688000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	110700000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	55400000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	46000000	usd
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	35700000	usd
CY2022Q3	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	100000	usd
	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	100000	usd
CY2021Q3	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	usd
	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	usd
CY2022Q3	us-gaap	Equity Method Investments EquityMethodInvestments	0	usd
CY2022Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	872000	usd
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3174000	usd
CY2022Q3	abus	Accrued Research And Development AccruedResearchAndDevelopment	8251000	usd
CY2021Q4	abus	Accrued Research And Development AccruedResearchAndDevelopment	2371000	usd
CY2022Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	315000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	983000	usd
CY2022Q3	abus	Accrued Payroll Current AccruedPayrollCurrent	2824000	usd
CY2021Q4	abus	Accrued Payroll Current AccruedPayrollCurrent	4279000	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	31000	usd
CY2022Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	12268000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	10838000	usd
CY2021Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	16296000	usd
CY2020Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	19554000	usd
	abus	Liability From Sale Of Future Royalties Non Cash Royalty Income LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome	5393000	usd
	abus	Liability From Sale Of Future Royalties Non Cash Royalty Income LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome	3963000	usd
	abus	Liability From Sale Of Future Royalties Non Cash Expense LiabilityFromSaleOfFutureRoyaltiesNonCashExpense	1413000	usd
	abus	Liability From Sale Of Future Royalties Non Cash Expense LiabilityFromSaleOfFutureRoyaltiesNonCashExpense	2292000	usd
CY2022Q3	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	12316000	usd
CY2021Q3	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	17883000	usd
	us-gaap	Premiums Earned Net PremiumsEarnedNet	4100000	usd
CY2022Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	25463000	usd
CY2022Q3	abus	Royalty Entitlements RoyaltyEntitlements	2	product
CY2022Q3	us-gaap	Revenues Revenues	5952000	usd
CY2021Q3	us-gaap	Revenues Revenues	3340000	usd
	us-gaap	Revenues Revenues	32774000	usd
	us-gaap	Revenues Revenues	7782000	usd
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1164000	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.37
CY2021Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.70
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.77
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.19
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1714000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1615000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5515000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4993000	usd
CY2021Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	22833922	shares

Files In Submission

Name	View Source	Status
0001447028-22-000055-index-headers.html	Edgar Link	pending
0001447028-22-000055-index.html	Edgar Link	pending
0001447028-22-000055.txt	Edgar Link	pending
0001447028-22-000055-xbrl.zip	Edgar Link	pending
a2022-q310xqex311.htm	Edgar Link	pending
a2022-q310xqex312.htm	Edgar Link	pending
a2022-q310xqex321.htm	Edgar Link	pending
a2022-q310xqex322.htm	Edgar Link	pending
abus-20220930.htm	Edgar Link	pending
abus-20220930.xsd	Edgar Link	pending
abus-20220930_g1.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
abus-20220930_cal.xml	Edgar Link	unprocessable
abus-20220930_def.xml	Edgar Link	unprocessable
abus-20220930_lab.xml	Edgar Link	unprocessable
abus-20220930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
abus-20220930_htm.xml	Edgar Link	completed
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABUS
Arbutus Biopharma Corp Stock $abus

2022 Q4 Form 10-Q Financial Statement

#000144702822000055 Filed on November 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS Arbutus Biopharma Corp Stock $abus

2022 Q4 Form 10-Q Financial Statement

#000144702822000055 Filed on November 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS
Arbutus Biopharma Corp Stock $abus